Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of 明复乐 (rhTNK-tPA) for acute ischemic stroke treated 4.5-24 hours after onset
CTR20253900Phase 3Active
- Sponsor
- CSPC Mingfule Pharmaceutical
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase in ischemic stroke, sponsored by CSPC Mingfule Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20253900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253900.